Back

Real world data on adopting guideline directed medical therapy post 2021 ESC HF guidelines and effect on renal function.

27 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Marco Ferrari

University of Brescia, Brescia (Italy)

7 More presentations in this session

Presentation thumbnail
Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure
Doctor Y. Nishihara (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Use of guideline-recommended heart failure drugs in high-, middle- and low-income countries: a systematic review and meta-analysis
Associate Professor S. Peters (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Candidacy and predicted efficacy of vericiguat in contemporary heart failure outpatient clinics
Doctor B. Soh (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Quadruple therapy for heart failure before and after electronic cardiac device implantation - are we hitting our targets?
Doctor F. Rode (Zagreb, HR)
Abstract Slides Video
Presentation thumbnail
The management of patients with heart failure in Sweden: a survey conducted among physicians in Sweden
Doctor G. Ferrannini (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in heart failure

The Event

Event poster

ESC Congress 2023

27 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
In a patient with worsening renal function
thumbnail
Congress Presentation
ESC Heart Failure
thumbnail
Congress Session
Personalised therapy in heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources